Kailera makes history with record-breaking $625m IPO
Obesity biotech Kailera Therapeutics has set its sights on the US public market through an upsized $625m IPO, marking one …
Post
-
-
Aligos and Xiamen Amoytop sign deal for HBV therapy
Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium …
-
The innovators working to make in vivo cell therapy a reality
As investors signal early interest in in vivo cell therapies and raise the modality’s potential for commercial success, a growing …
-
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor …
-
Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less …
-
Lilly debuts more Foundayo data as FDA requests post-marketing trials
Eli Lilly has released more data for its obesity pill, Foundayo (orforglipron) in a rapid response to US regulators voicing …
-
Terremoto wins $108m in Series C to drive cancer and rare disease programmes
Terremoto Biosciences has closed a Series C financing round worth $108m, which will allow the company to usher its range …
-
Nucleai and Sirona Dx to provide new proteomics solution for pharma companies
Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology businesses for drug …
-
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for …
-
FDA shares guide on genome editing best practices
The US Food and Drug Administration (FDA) has debuted draft guidance for gene therapy developers, focused on the use of …
-
Amazon launches AI drug discovery platform
Amazon Web Services (AWS) is launching an artificial intelligence (AI) application to design and test novel drugs more quickly and …
-
J&J sets the tone for Q1 earnings with strong oncology growth
As companies across the life sciences space gear up to debut their Q1 earnings, Johnson & Johnson (J&J) has kicked …
-
Adcendo secures $75m in Series C funding for ADC development
Adcendo, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for cancer treatment, has raised $75m in a Series C funding …
-
Lilly to acquire CrossBridge Bio for up to $300m
Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, …
-
EU sees 2025 pharma export uptick amid competitiveness concerns
New figures debuted by the European Union (EU) have uncovered a significant rise in the year-on-year value of pharma trade …
